English

NovoCure Limited

EDGAR

NVCR Current report (8-K) · filed 2026-10-29

Annual consolidated revenue for 2025: about USD 655.4M, using the latest reported figures. The previous period, 2024, was about USD 605.2M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

193 million USD

2026 Q3 · USD

Exact inputs and evidence

Revenue: 193399000 USD Source

Operating margin

-3.19%

2026 Q3 · %

Exact inputs and evidence

Operating Income: -6171000 USD Source
Revenue: 193399000 USD Source

Operating cash flow

22.7 million USD

2026 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: 22667000 USD Source

Free cash flow

15.7 million USD

2026 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: 22667000 USD Source
Capital Expenditure: 6921000 USD Source

Cash and cash equivalents: 96.7 million USD 2026-09-30 Source
Exact value

96734000 USD
Long-term debt including current maturities: 569 million USD 2023-12-31 Source
Exact value

568822000 USD
Shares outstanding: 117 million shares 2026-09-30 Source
Exact value

116914114 shares

Reported share-count change

4.41% · 4.93 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

111979981 shares · 2025-09-30· Source
116914114 shares · 2026-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

725 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence

Revenue: 655353000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 481003000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 174055000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 183584000 USD · 2026-04-01 – 2026-06-30 Source
Revenue: 193399000 USD · 2026-07-01 – 2026-09-30 Source

Net income

-122 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence

Net income: -136227000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -111728000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -71138000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -15658000 USD · 2026-04-01 – 2026-06-30 Source
Net income: -10435000 USD · 2026-07-01 – 2026-09-30 Source

Operating cash flow

-722 thousand USD

2025-10-01 – 2026-09-30

Exact inputs and evidence

Operating cash flow: -49031000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -31027000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -13517000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: 8132000 USD · 2026-04-01 – 2026-06-30 Source
Operating cash flow: 22667000 USD · 2026-07-01 – 2026-09-30 Source

Capital expenditure

23.9 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence

Capital expenditure: 26648000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 21752000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 5152000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 6916000 USD · 2026-04-01 – 2026-06-30 Source
Capital expenditure: 6921000 USD · 2026-07-01 – 2026-09-30 Source

Free cash flow

-24.6 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence

Operating cash flow: -49031000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -31027000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -13517000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: 8132000 USD · 2026-04-01 – 2026-06-30 Source
Operating cash flow: 22667000 USD · 2026-07-01 – 2026-09-30 Source
Capital expenditure: 26648000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 21752000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 5152000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 6916000 USD · 2026-04-01 – 2026-06-30 Source
Capital expenditure: 6921000 USD · 2026-07-01 – 2026-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-29.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 5 of 11 periods available· newest 2023-12-31
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+8.3%

Prior period

USD 605.22 million

2024-01-01 – 2024-12-31
Current period

USD 655.35 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

655353000 − 605220000 = 50133000 USD

605220000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
655353000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · NovoCure Limited · 2025-12-31 NovoCure Limited (edgar:1645113) Year-over-year change in Revenue: 50133000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 655353000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000080/nvcr-20260930.htm#794413 Filing: 000164511326000080 Input fundies:Revenue: 605220000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm#1664029 Filing: 000164511326000017
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 32.4 million

Prior period

−USD 168.63 million

2024-01-01 – 2024-12-31
Current period

−USD 136.23 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-136227000 − -168627000 = 32400000 USD

-168627000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-136227000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · NovoCure Limited · 2025-12-31 NovoCure Limited (edgar:1645113) Year-over-year change in Net income: 32400000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -136227000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000080/nvcr-20260930.htm#914014 Filing: 000164511326000080 Input fundies:NetIncome: -168627000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm#2083843 Filing: 000164511326000017
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 22.66 million

Prior period

−USD 26.37 million

2024-01-01 – 2024-12-31
Current period

−USD 49.03 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-49031000 − -26369000 = -22662000 USD

-26369000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-49031000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · NovoCure Limited · 2025-12-31 NovoCure Limited (edgar:1645113) Year-over-year change in Operating cash flow: -22662000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -49031000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000080/nvcr-20260930.htm#482428 Filing: 000164511326000080 Input fundies:OperatingCashFlow: -26369000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm#1161997 Filing: 000164511326000017
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-37.8%

Prior period

USD 42.86 million

2024-01-01 – 2024-12-31
Current period

USD 26.65 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

26648000 − 42855000 = -16207000 USD

42855000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
26648000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · NovoCure Limited · 2025-12-31 NovoCure Limited (edgar:1645113) Year-over-year change in Capital expenditure: -16207000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 26648000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000080/nvcr-20260930.htm#487341 Filing: 000164511326000080 Input fundies:CapitalExpenditure: 42855000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm#1164990 Filing: 000164511326000017
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 655.35 million 100% of revenue
Cost of revenue USD 166.88 million 25% of revenue
Operating expenses USD 642.27 million 98% of revenue
Operating income −USD 153.8 million −23% of revenue
Tax, interest and other Derived −USD 17.57 million −2.7% of revenue
Net income −USD 136.23 million −21% of revenue

Cash

Operating cash flow −USD 49.03 million −7.5% of revenue
Capital expenditure USD 26.65 million 4.1% of revenue
Free cash flow Derived −USD 75.68 million −12% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 239% of revenue.
2017 Operating loss: operating costs were 122% of revenue.
2018 Operating loss: operating costs were 114% of revenue.
2019 Operating loss: operating costs were 100% of revenue.
2020 94%
2021 Operating loss: operating costs were 108% of revenue.
2022 Operating loss: operating costs were 117% of revenue.
2023 Operating loss: operating costs were 146% of revenue.
2024 Operating loss: operating costs were 128% of revenue.
2025 Operating loss: operating costs were 123% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	82888000	198205000 Derived	-115317000	16528000 Derived	-131845000	-113265000 Derived	Source 2016-01-01 – 2016-12-31: 82888000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -115317000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -131845000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -107592000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 5673000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	177026000	216354000 Derived	-39328000	22334000 Derived	-61662000	-40500000 Derived	Source 2017-01-01 – 2017-12-31: 177026000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -39328000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -61662000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -33134000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 7366000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	248069000	281741000 Derived	-33672000	29887000 Derived	-63559000	-8576000 Derived	Source 2018-01-01 – 2018-12-31: 248069000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -33672000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -63559000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -1865000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 6711000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	351318000	352232000 Derived	-914000	6316000 Derived	-7230000	16135000 Derived	Source 2019-01-01 – 2019-12-31: 351318000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -914000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -7230000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 26620000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 10485000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	494366000	463965000 Derived	30401000	10593000 Derived	19808000	84180000 Derived	Source 2020-01-01 – 2020-12-31: 494366000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: 30401000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: 19808000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 99148000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 14968000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	535031000	579364000 Derived	-44333000	14018000 Derived	-58351000	58586000 Derived	Source 2021-01-01 – 2021-12-31: 535031000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -44333000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -58351000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 82756000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 24170000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	537840000	627363000 Derived	-89523000	3011000 Derived	-92534000	9430000 Derived	Source 2022-01-01 – 2022-12-31: 537840000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -89523000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -92534000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: 30788000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 21358000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	509338000	742208000 Derived	-232870000	-25827000 Derived	-207043000	-100429000 Derived	Source 2023-01-01 – 2023-12-31: 509338000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -232870000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -207043000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -73336000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 27093000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	605220000	775716000 Derived	-170496000	-1869000 Derived	-168627000	-69224000 Derived	Source 2024-01-01 – 2024-12-31: 605220000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -170496000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -168627000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -26369000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 42855000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	655353000	809153000 Derived	-153800000	-17573000 Derived	-136227000	-75679000 Derived	Source 2025-01-01 – 2025-12-31: 655353000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -153800000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -136227000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -49031000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 26648000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 655.4M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	82888000	Revenue: 82888000 Open source
20172017-12-31	Revenue	177026000	Revenue: 177026000 Open source
20182018-12-31	Revenue	248069000	Revenue: 248069000 Open source
20192019-12-31	Revenue	351318000	Revenue: 351318000 Open source
20202020-12-31	Revenue	494366000	Revenue: 494366000 Open source
20212021-12-31	Revenue	535031000	Revenue: 535031000 Open source
20222022-12-31	Revenue	537840000	Revenue: 537840000 Open source
20232023-12-31	Revenue	509338000	Revenue: 509338000 Open source
20242024-12-31	Revenue	605220000	Revenue: 605220000 Open source
20252025-12-31	Revenue	655353000	Revenue: 655353000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

8.3% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	150.5%	Revenue: 82888000 Open source Revenue: 33087000 Open source
20172017-12-31	Year over year	113.6%	Revenue: 177026000 Open source Revenue: 82888000 Open source
20182018-12-31	Year over year	40.1%	Revenue: 248069000 Open source Revenue: 177026000 Open source
20192019-12-31	Year over year	41.6%	Revenue: 351318000 Open source Revenue: 248069000 Open source
20202020-12-31	Year over year	40.7%	Revenue: 494366000 Open source Revenue: 351318000 Open source
20212021-12-31	Year over year	8.2%	Revenue: 535031000 Open source Revenue: 494366000 Open source
20222022-12-31	Year over year	0.5%	Revenue: 537840000 Open source Revenue: 535031000 Open source
20232023-12-31	Year over year	-5.3%	Revenue: 509338000 Open source Revenue: 537840000 Open source
20242024-12-31	Year over year	18.8%	Revenue: 605220000 Open source Revenue: 509338000 Open source
20252025-12-31	Year over year	8.3%	Revenue: 655353000 Open source Revenue: 605220000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -23.5% 2025

Net margin -20.8% 2025

Free cash flow margin -11.5% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-139.1%	Operating Income: -115317000 Open source Revenue: 82888000 Open source
20172017-12-31	Operating margin	-22.2%	Operating Income: -39328000 Open source Revenue: 177026000 Open source
20182018-12-31	Operating margin	-13.6%	Operating Income: -33672000 Open source Revenue: 248069000 Open source
20192019-12-31	Operating margin	-0.3%	Operating Income: -914000 Open source Revenue: 351318000 Open source
20202020-12-31	Operating margin	6.1%	Operating Income: 30401000 Open source Revenue: 494366000 Open source
20212021-12-31	Operating margin	-8.3%	Operating Income: -44333000 Open source Revenue: 535031000 Open source
20222022-12-31	Operating margin	-16.6%	Operating Income: -89523000 Open source Revenue: 537840000 Open source
20232023-12-31	Operating margin	-45.7%	Operating Income: -232870000 Open source Revenue: 509338000 Open source
20242024-12-31	Operating margin	-28.2%	Operating Income: -170496000 Open source Revenue: 605220000 Open source
20252025-12-31	Operating margin	-23.5%	Operating Income: -153800000 Open source Revenue: 655353000 Open source
20162016-12-31	Net margin	-159.1%	Net Income: -131845000 Open source Revenue: 82888000 Open source
20172017-12-31	Net margin	-34.8%	Net Income: -61662000 Open source Revenue: 177026000 Open source
20182018-12-31	Net margin	-25.6%	Net Income: -63559000 Open source Revenue: 248069000 Open source
20192019-12-31	Net margin	-2.1%	Net Income: -7230000 Open source Revenue: 351318000 Open source
20202020-12-31	Net margin	4%	Net Income: 19808000 Open source Revenue: 494366000 Open source
20212021-12-31	Net margin	-10.9%	Net Income: -58351000 Open source Revenue: 535031000 Open source
20222022-12-31	Net margin	-17.2%	Net Income: -92534000 Open source Revenue: 537840000 Open source
20232023-12-31	Net margin	-40.6%	Net Income: -207043000 Open source Revenue: 509338000 Open source
20242024-12-31	Net margin	-27.9%	Net Income: -168627000 Open source Revenue: 605220000 Open source
20252025-12-31	Net margin	-20.8%	Net Income: -136227000 Open source Revenue: 655353000 Open source
20162016-12-31	Free cash flow margin	-136.6%	Revenue: 82888000 Open source Operating Cash Flow: -107592000 Open source Capital Expenditure: 5673000 Open source
20172017-12-31	Free cash flow margin	-22.9%	Revenue: 177026000 Open source Operating Cash Flow: -33134000 Open source Capital Expenditure: 7366000 Open source
20182018-12-31	Free cash flow margin	-3.5%	Revenue: 248069000 Open source Operating Cash Flow: -1865000 Open source Capital Expenditure: 6711000 Open source
20192019-12-31	Free cash flow margin	4.6%	Revenue: 351318000 Open source Operating Cash Flow: 26620000 Open source Capital Expenditure: 10485000 Open source
20202020-12-31	Free cash flow margin	17%	Revenue: 494366000 Open source Operating Cash Flow: 99148000 Open source Capital Expenditure: 14968000 Open source
20212021-12-31	Free cash flow margin	11%	Revenue: 535031000 Open source Operating Cash Flow: 82756000 Open source Capital Expenditure: 24170000 Open source
20222022-12-31	Free cash flow margin	1.8%	Revenue: 537840000 Open source Operating Cash Flow: 30788000 Open source Capital Expenditure: 21358000 Open source
20232023-12-31	Free cash flow margin	-19.7%	Revenue: 509338000 Open source Operating Cash Flow: -73336000 Open source Capital Expenditure: 27093000 Open source
20242024-12-31	Free cash flow margin	-11.4%	Revenue: 605220000 Open source Operating Cash Flow: -26369000 Open source Capital Expenditure: 42855000 Open source
20252025-12-31	Free cash flow margin	-11.5%	Revenue: 655353000 Open source Operating Cash Flow: -49031000 Open source Capital Expenditure: 26648000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -49M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-107592000	Operating Cash Flow: -107592000 Open source
20172017-12-31	Operating cash flow	-33134000	Operating Cash Flow: -33134000 Open source
20182018-12-31	Operating cash flow	-1865000	Operating Cash Flow: -1865000 Open source
20192019-12-31	Operating cash flow	26620000	Operating Cash Flow: 26620000 Open source
20202020-12-31	Operating cash flow	99148000	Operating Cash Flow: 99148000 Open source
20212021-12-31	Operating cash flow	82756000	Operating Cash Flow: 82756000 Open source
20222022-12-31	Operating cash flow	30788000	Operating Cash Flow: 30788000 Open source
20232023-12-31	Operating cash flow	-73336000	Operating Cash Flow: -73336000 Open source
20242024-12-31	Operating cash flow	-26369000	Operating Cash Flow: -26369000 Open source
20252025-12-31	Operating cash flow	-49031000	Operating Cash Flow: -49031000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -75.7M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-113265000	Operating Cash Flow: -107592000 Open source Capital Expenditure: 5673000 Open source
20172017-12-31	Free cash flow	-40500000	Operating Cash Flow: -33134000 Open source Capital Expenditure: 7366000 Open source
20182018-12-31	Free cash flow	-8576000	Operating Cash Flow: -1865000 Open source Capital Expenditure: 6711000 Open source
20192019-12-31	Free cash flow	16135000	Operating Cash Flow: 26620000 Open source Capital Expenditure: 10485000 Open source
20202020-12-31	Free cash flow	84180000	Operating Cash Flow: 99148000 Open source Capital Expenditure: 14968000 Open source
20212021-12-31	Free cash flow	58586000	Operating Cash Flow: 82756000 Open source Capital Expenditure: 24170000 Open source
20222022-12-31	Free cash flow	9430000	Operating Cash Flow: 30788000 Open source Capital Expenditure: 21358000 Open source
20232023-12-31	Free cash flow	-100429000	Operating Cash Flow: -73336000 Open source Capital Expenditure: 27093000 Open source
20242024-12-31	Free cash flow	-69224000	Operating Cash Flow: -26369000 Open source Capital Expenditure: 42855000 Open source
20252025-12-31	Free cash flow	-75679000	Operating Cash Flow: -49031000 Open source Capital Expenditure: 26648000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

57.7% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	49.5%	Total Liabilities: 139736000 Open source Total Assets: 282081000 Open source
20172017-12-31	Liabilities / assets	57.2%	Total Liabilities: 151734000 Open source Total Assets: 265298000 Open source
20182018-12-31	Liabilities / assets	67%	Total Liabilities: 227534000 Open source Total Assets: 339793000 Open source
20192019-12-31	Liabilities / assets	54.6%	Total Liabilities: 261658000 Open source Total Assets: 479448000 Open source
20202020-12-31	Liabilities / assets	54.7%	Total Liabilities: 575457000 Open source Total Assets: 1051983000 Open source
20212021-12-31	Liabilities / assets	64%	Total Liabilities: 729001000 Open source Total Assets: 1139495000 Open source
20222022-12-31	Liabilities / assets	63%	Total Liabilities: 750478000 Open source Total Assets: 1191648000 Open source
20232023-12-31	Liabilities / assets	68.4%	Total Liabilities: 783633000 Open source Total Assets: 1146129000 Open source
20242024-12-31	Liabilities / assets	71%	Total Liabilities: 880605000 Open source Total Assets: 1240784000 Open source
20252025-12-31	Liabilities / assets	57.7%	Total Liabilities: 463860000 Open source Total Assets: 804326000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.9× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	7.1×	Current Assets: 261873000 Open source Current Liabilities: 36882000 Open source
20172017-12-31	Current assets / current liabilities	4.88×	Current Assets: 245134000 Open source Current Liabilities: 50202000 Open source
20182018-12-31	Current assets / current liabilities	4.98×	Current Assets: 321369000 Open source Current Liabilities: 64560000 Open source
20192019-12-31	Current assets / current liabilities	5.1×	Current Assets: 439947000 Open source Current Liabilities: 86311000 Open source
20202020-12-31	Current assets / current liabilities	8.8×	Current Assets: 999441000 Open source Current Liabilities: 113612000 Open source
20212021-12-31	Current assets / current liabilities	7.53×	Current Assets: 1073526000 Open source Current Liabilities: 142602000 Open source
20222022-12-31	Current assets / current liabilities	7×	Current Assets: 1111529000 Open source Current Liabilities: 158777000 Open source
20232023-12-31	Current assets / current liabilities	5.78×	Current Assets: 1034409000 Open source Current Liabilities: 179115000 Open source
20242024-12-31	Current assets / current liabilities	1.46×	Current Assets: 1106575000 Open source Current Liabilities: 756394000 Open source
20252025-12-31	Current assets / current liabilities	2.9×	Current Assets: 646731000 Open source Current Liabilities: 223228000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 131.85 million Exact value Exact value: -131845000 USD 2016-01-01 – 2016-12-31: -131845000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NovoCure Limited · 2016-12-31 NovoCure Limited (edgar:1645113) Net Income: -131845000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -131845000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000156459019005146/nvcr-20181231.xml#141149 Filing: 000156459019005146 The citation records this snapshot. The page link may show a newer release later.	−USD 107.59 million Exact value Exact value: -107592000 USD 2016-01-01 – 2016-12-31: -107592000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NovoCure Limited · 2016-12-31 NovoCure Limited (edgar:1645113) Operating Cash Flow: -107592000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -107592000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000156459019005146/nvcr-20181231.xml#168617 Filing: 000156459019005146 The citation records this snapshot. The page link may show a newer release later.	USD 5.67 million Exact value Exact value: 5673000 USD 2016-01-01 – 2016-12-31: 5673000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NovoCure Limited · 2016-12-31 NovoCure Limited (edgar:1645113) Capital Expenditure: 5673000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5673000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000156459019005146/nvcr-20181231.xml#169250 Filing: 000156459019005146 The citation records this snapshot. The page link may show a newer release later.	−USD 113.27 million Calculation and evidence -107592000 − 5673000 USD Exact free cash flow: -113265000 USD 2016-01-01 – 2016-12-31: -107592000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 5673000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NovoCure Limited · 2016-12-31 NovoCure Limited (edgar:1645113) Free cash flow: -113265000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -107592000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000156459019005146/nvcr-20181231.xml#168617 Filing: 000156459019005146 Input fundies:CapitalExpenditure: 5673000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000156459019005146/nvcr-20181231.xml#169250 Filing: 000156459019005146 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 61.66 million Exact value Exact value: -61662000 USD 2017-01-01 – 2017-12-31: -61662000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NovoCure Limited · 2017-12-31 NovoCure Limited (edgar:1645113) Net Income: -61662000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -61662000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511320000025/nvcr-20191231.htm#2963649 Filing: 000164511320000025 The citation records this snapshot. The page link may show a newer release later.	−USD 33.13 million Exact value Exact value: -33134000 USD 2017-01-01 – 2017-12-31: -33134000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NovoCure Limited · 2017-12-31 NovoCure Limited (edgar:1645113) Operating Cash Flow: -33134000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33134000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511320000025/nvcr-20191231.htm#1803788 Filing: 000164511320000025 The citation records this snapshot. The page link may show a newer release later.	USD 7.37 million Exact value Exact value: 7366000 USD 2017-01-01 – 2017-12-31: 7366000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NovoCure Limited · 2017-12-31 NovoCure Limited (edgar:1645113) Capital Expenditure: 7366000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7366000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511320000025/nvcr-20191231.htm#1808967 Filing: 000164511320000025 The citation records this snapshot. The page link may show a newer release later.	−USD 40.5 million Calculation and evidence -33134000 − 7366000 USD Exact free cash flow: -40500000 USD 2017-01-01 – 2017-12-31: -33134000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 7366000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NovoCure Limited · 2017-12-31 NovoCure Limited (edgar:1645113) Free cash flow: -40500000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33134000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511320000025/nvcr-20191231.htm#1803788 Filing: 000164511320000025 Input fundies:CapitalExpenditure: 7366000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511320000025/nvcr-20191231.htm#1808967 Filing: 000164511320000025 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 63.56 million Exact value Exact value: -63559000 USD 2018-01-01 – 2018-12-31: -63559000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NovoCure Limited · 2018-12-31 NovoCure Limited (edgar:1645113) Net Income: -63559000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -63559000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511321000017/nvcr-20201231.htm#2225144 Filing: 000164511321000017 The citation records this snapshot. The page link may show a newer release later.	−USD 1.87 million Exact value Exact value: -1865000 USD 2018-01-01 – 2018-12-31: -1865000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NovoCure Limited · 2018-12-31 NovoCure Limited (edgar:1645113) Operating Cash Flow: -1865000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1865000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511321000017/nvcr-20201231.htm#1327123 Filing: 000164511321000017 The citation records this snapshot. The page link may show a newer release later.	USD 6.71 million Exact value Exact value: 6711000 USD 2018-01-01 – 2018-12-31: 6711000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NovoCure Limited · 2018-12-31 NovoCure Limited (edgar:1645113) Capital Expenditure: 6711000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6711000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511321000017/nvcr-20201231.htm#1330996 Filing: 000164511321000017 The citation records this snapshot. The page link may show a newer release later.	−USD 8.58 million Calculation and evidence -1865000 − 6711000 USD Exact free cash flow: -8576000 USD 2018-01-01 – 2018-12-31: -1865000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 6711000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NovoCure Limited · 2018-12-31 NovoCure Limited (edgar:1645113) Free cash flow: -8576000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1865000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511321000017/nvcr-20201231.htm#1327123 Filing: 000164511321000017 Input fundies:CapitalExpenditure: 6711000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511321000017/nvcr-20201231.htm#1330996 Filing: 000164511321000017 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 7.23 million Exact value Exact value: -7230000 USD 2019-01-01 – 2019-12-31: -7230000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NovoCure Limited · 2019-12-31 NovoCure Limited (edgar:1645113) Net Income: -7230000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7230000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511322000011/nvcr-20211231.htm#2150362 Filing: 000164511322000011 The citation records this snapshot. The page link may show a newer release later.	USD 26.62 million Exact value Exact value: 26620000 USD 2019-01-01 – 2019-12-31: 26620000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NovoCure Limited · 2019-12-31 NovoCure Limited (edgar:1645113) Operating Cash Flow: 26620000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 26620000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511322000011/nvcr-20211231.htm#1200116 Filing: 000164511322000011 The citation records this snapshot. The page link may show a newer release later.	USD 10.49 million Exact value Exact value: 10485000 USD 2019-01-01 – 2019-12-31: 10485000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NovoCure Limited · 2019-12-31 NovoCure Limited (edgar:1645113) Capital Expenditure: 10485000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10485000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511322000011/nvcr-20211231.htm#1204007 Filing: 000164511322000011 The citation records this snapshot. The page link may show a newer release later.	USD 16.14 million Calculation and evidence 26620000 − 10485000 USD Exact free cash flow: 16135000 USD 2019-01-01 – 2019-12-31: 26620000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 10485000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NovoCure Limited · 2019-12-31 NovoCure Limited (edgar:1645113) Free cash flow: 16135000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 26620000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511322000011/nvcr-20211231.htm#1200116 Filing: 000164511322000011 Input fundies:CapitalExpenditure: 10485000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511322000011/nvcr-20211231.htm#1204007 Filing: 000164511322000011 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	USD 19.81 million Exact value Exact value: 19808000 USD 2020-01-01 – 2020-12-31: 19808000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NovoCure Limited · 2020-12-31 NovoCure Limited (edgar:1645113) Net Income: 19808000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: 19808000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000023/nvcr-20221231.htm#2299602 Filing: 000164511323000023 The citation records this snapshot. The page link may show a newer release later.	USD 99.15 million Exact value Exact value: 99148000 USD 2020-01-01 – 2020-12-31: 99148000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NovoCure Limited · 2020-12-31 NovoCure Limited (edgar:1645113) Operating Cash Flow: 99148000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 99148000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000023/nvcr-20221231.htm#1215615 Filing: 000164511323000023 The citation records this snapshot. The page link may show a newer release later.	USD 14.97 million Exact value Exact value: 14968000 USD 2020-01-01 – 2020-12-31: 14968000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NovoCure Limited · 2020-12-31 NovoCure Limited (edgar:1645113) Capital Expenditure: 14968000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 14968000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000023/nvcr-20221231.htm#1219506 Filing: 000164511323000023 The citation records this snapshot. The page link may show a newer release later.	USD 84.18 million Calculation and evidence 99148000 − 14968000 USD Exact free cash flow: 84180000 USD 2020-01-01 – 2020-12-31: 99148000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 14968000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NovoCure Limited · 2020-12-31 NovoCure Limited (edgar:1645113) Free cash flow: 84180000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 99148000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000023/nvcr-20221231.htm#1215615 Filing: 000164511323000023 Input fundies:CapitalExpenditure: 14968000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000023/nvcr-20221231.htm#1219506 Filing: 000164511323000023 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 58.35 million Exact value Exact value: -58351000 USD 2021-01-01 – 2021-12-31: -58351000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NovoCure Limited · 2021-12-31 NovoCure Limited (edgar:1645113) Net Income: -58351000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -58351000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000006/nvcr-20231231.htm#1902064 Filing: 000164511324000006 The citation records this snapshot. The page link may show a newer release later.	USD 82.76 million Exact value Exact value: 82756000 USD 2021-01-01 – 2021-12-31: 82756000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NovoCure Limited · 2021-12-31 NovoCure Limited (edgar:1645113) Operating Cash Flow: 82756000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 82756000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000006/nvcr-20231231.htm#1109215 Filing: 000164511324000006 The citation records this snapshot. The page link may show a newer release later.	USD 24.17 million Exact value Exact value: 24170000 USD 2021-01-01 – 2021-12-31: 24170000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NovoCure Limited · 2021-12-31 NovoCure Limited (edgar:1645113) Capital Expenditure: 24170000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 24170000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000006/nvcr-20231231.htm#1111911 Filing: 000164511324000006 The citation records this snapshot. The page link may show a newer release later.	USD 58.59 million Calculation and evidence 82756000 − 24170000 USD Exact free cash flow: 58586000 USD 2021-01-01 – 2021-12-31: 82756000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 24170000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NovoCure Limited · 2021-12-31 NovoCure Limited (edgar:1645113) Free cash flow: 58586000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 82756000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000006/nvcr-20231231.htm#1109215 Filing: 000164511324000006 Input fundies:CapitalExpenditure: 24170000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000006/nvcr-20231231.htm#1111911 Filing: 000164511324000006 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 92.53 million Exact value Exact value: -92534000 USD 2022-01-01 – 2022-12-31: -92534000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NovoCure Limited · 2022-12-31 NovoCure Limited (edgar:1645113) Net Income: -92534000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -92534000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000002/nvcr-20241231.htm#1984384 Filing: 000164511325000002 The citation records this snapshot. The page link may show a newer release later.	USD 30.79 million Exact value Exact value: 30788000 USD 2022-01-01 – 2022-12-31: 30788000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NovoCure Limited · 2022-12-31 NovoCure Limited (edgar:1645113) Operating Cash Flow: 30788000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 30788000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000002/nvcr-20241231.htm#1159341 Filing: 000164511325000002 The citation records this snapshot. The page link may show a newer release later.	USD 21.36 million Exact value Exact value: 21358000 USD 2022-01-01 – 2022-12-31: 21358000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NovoCure Limited · 2022-12-31 NovoCure Limited (edgar:1645113) Capital Expenditure: 21358000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21358000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000002/nvcr-20241231.htm#1162037 Filing: 000164511325000002 The citation records this snapshot. The page link may show a newer release later.	USD 9.43 million Calculation and evidence 30788000 − 21358000 USD Exact free cash flow: 9430000 USD 2022-01-01 – 2022-12-31: 30788000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 21358000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NovoCure Limited · 2022-12-31 NovoCure Limited (edgar:1645113) Free cash flow: 9430000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 30788000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000002/nvcr-20241231.htm#1159341 Filing: 000164511325000002 Input fundies:CapitalExpenditure: 21358000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000002/nvcr-20241231.htm#1162037 Filing: 000164511325000002 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 207.04 million Exact value Exact value: -207043000 USD 2023-01-01 – 2023-12-31: -207043000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NovoCure Limited · 2023-12-31 NovoCure Limited (edgar:1645113) Net Income: -207043000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -207043000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm#2084695 Filing: 000164511326000017 The citation records this snapshot. The page link may show a newer release later.	−USD 73.34 million Exact value Exact value: -73336000 USD 2023-01-01 – 2023-12-31: -73336000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NovoCure Limited · 2023-12-31 NovoCure Limited (edgar:1645113) Operating Cash Flow: -73336000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -73336000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm#1162876 Filing: 000164511326000017 The citation records this snapshot. The page link may show a newer release later.	USD 27.09 million Exact value Exact value: 27093000 USD 2023-01-01 – 2023-12-31: 27093000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NovoCure Limited · 2023-12-31 NovoCure Limited (edgar:1645113) Capital Expenditure: 27093000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 27093000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm#1165576 Filing: 000164511326000017 The citation records this snapshot. The page link may show a newer release later.	−USD 100.43 million Calculation and evidence -73336000 − 27093000 USD Exact free cash flow: -100429000 USD 2023-01-01 – 2023-12-31: -73336000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 27093000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NovoCure Limited · 2023-12-31 NovoCure Limited (edgar:1645113) Free cash flow: -100429000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -73336000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm#1162876 Filing: 000164511326000017 Input fundies:CapitalExpenditure: 27093000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm#1165576 Filing: 000164511326000017 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 168.63 million Exact value Exact value: -168627000 USD 2024-01-01 – 2024-12-31: -168627000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NovoCure Limited · 2024-12-31 NovoCure Limited (edgar:1645113) Net Income: -168627000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -168627000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm#2083843 Filing: 000164511326000017 The citation records this snapshot. The page link may show a newer release later.	−USD 26.37 million Exact value Exact value: -26369000 USD 2024-01-01 – 2024-12-31: -26369000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NovoCure Limited · 2024-12-31 NovoCure Limited (edgar:1645113) Operating Cash Flow: -26369000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -26369000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm#1161997 Filing: 000164511326000017 The citation records this snapshot. The page link may show a newer release later.	USD 42.86 million Exact value Exact value: 42855000 USD 2024-01-01 – 2024-12-31: 42855000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NovoCure Limited · 2024-12-31 NovoCure Limited (edgar:1645113) Capital Expenditure: 42855000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 42855000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm#1164990 Filing: 000164511326000017 The citation records this snapshot. The page link may show a newer release later.	−USD 69.22 million Calculation and evidence -26369000 − 42855000 USD Exact free cash flow: -69224000 USD 2024-01-01 – 2024-12-31: -26369000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 42855000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NovoCure Limited · 2024-12-31 NovoCure Limited (edgar:1645113) Free cash flow: -69224000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -26369000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm#1161997 Filing: 000164511326000017 Input fundies:CapitalExpenditure: 42855000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm#1164990 Filing: 000164511326000017 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 136.23 million Exact value Exact value: -136227000 USD 2025-01-01 – 2025-12-31: -136227000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NovoCure Limited · 2025-12-31 NovoCure Limited (edgar:1645113) Net Income: -136227000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -136227000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000080/nvcr-20260930.htm#914014 Filing: 000164511326000080 The citation records this snapshot. The page link may show a newer release later.	−USD 49.03 million Exact value Exact value: -49031000 USD 2025-01-01 – 2025-12-31: -49031000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NovoCure Limited · 2025-12-31 NovoCure Limited (edgar:1645113) Operating Cash Flow: -49031000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -49031000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000080/nvcr-20260930.htm#482428 Filing: 000164511326000080 The citation records this snapshot. The page link may show a newer release later.	USD 26.65 million Exact value Exact value: 26648000 USD 2025-01-01 – 2025-12-31: 26648000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NovoCure Limited · 2025-12-31 NovoCure Limited (edgar:1645113) Capital Expenditure: 26648000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 26648000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000080/nvcr-20260930.htm#487341 Filing: 000164511326000080 The citation records this snapshot. The page link may show a newer release later.	−USD 75.68 million Calculation and evidence -49031000 − 26648000 USD Exact free cash flow: -75679000 USD 2025-01-01 – 2025-12-31: -49031000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 26648000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NovoCure Limited · 2025-12-31 NovoCure Limited (edgar:1645113) Free cash flow: -75679000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:03:42Z Snapshot: 7d50330aba5bcce8d90df3392eb182da3cc20b518413982431e9fc30f077a22a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645113?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -49031000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000080/nvcr-20260930.htm#482428 Filing: 000164511326000080 Input fundies:CapitalExpenditure: 26648000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000080/nvcr-20260930.htm#487341 Filing: 000164511326000080 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

139 filings · 3,770 latest values · 3,770 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001645113, 1645113, NVCR, edgar:1645113

Also known as NovoCure Limited, NovoCure Ltd, Novocure Ltd

NovoCure Limited

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation